BIO-acetoxime（Cat No.: I004263）, is a powerful dual inhibitor targeting both GSK3α and GSK3β with impressive potency, characterized by an IC50 of 10 nM. What sets BIO-acetoxime apart is its remarkable selectivity, demonstrating over 240-fold specificity when compared to CDK5/p25, CDK2/cyclin A, and CDK1/cyclin B. This selectivity is particularly advantageous for research focusing on GSK3-related cellular processes, such as cell signaling and regulation. If you require additional information or assistance regarding BIO-ketoxime, please feel free to contact us.
| Catalog Number | I004263 |
| CAS Number | 667463-85-6 |
| Synonyms | BIO-acetoxime; (2′Z,3′E)-6-Bromoindirubin-3′-acetoxime, 6-Bromoindirubin acetoxime, 6-Bromoindirubin-3′-acetoxime, BIA;(2Z,3E)-3-(acetoxyimino)-6/’-bromo-[2,3/’-biindolinylidene]-2/’-one |
| Molecular Formula | C18H12BrN3O3 |
| Purity | 95% |
| Target | GSK-3a/b inhibitor |
| Solubility | Soluble in DMSO, not in water |
| Storage | 2-8°C |
| IUPAC Name | [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate |
| InChI | InChI=1S/C18H12BrN3O3/c1-9(23)25-22-16-12-4-2-3-5-13(12)20-17(16)15-11-7-6-10(19)8-14(11)21-18(15)24/h2-8,21,24H,1H3/b22-16+ |
| InChIKey | HUDSYNWJCPDHLL-CJLVFECKSA-N |
| SMILES | CC(=O)ON=C1C2=CC=CC=C2N=C1C3=C(NC4=C3C=CC(=C4)Br)O |
| Reference | 1:Arch Virol. 2013 Jun;158(6):1287-96. doi: 10.1007/s00705-013-1629-3. Epub 2013 Feb 8. Antiherpetic potential of 6-bromoindirubin-3/’-acetoxime (BIO-acetoxime) in human oral epithelial cells.Hsu MJ,Hung SL, PMID: 23392633 DOI: 10.1007/s00705-013-1629-3 </br><span>Abstract:</span> Glycogen synthase kinase 3 (GSK-3) functions in the regulation of glycogen metabolism, in the cell cycle, and in immune responses and is targeted by some viruses to favor the viral life cycle. Inhibition of GSK-3 by 6-bromoindirubin-3/’-acetoxime (BIO-acetoxime), a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, protects cells from varicella infection. In this study, we examined the effects of BIO-acetoxime against herpes simplex virus-1 (HSV-1) infection in human oral epithelial cells, which represent a natural target cell type. The results revealed that BIO-acetoxime relieves HSV-1-induced cytopathic effects and apoptosis. We also found that BIO-acetoxime reduced viral yields and the expression of different classes of viral proteins. Furthermore, addition of BIO-acetoxime before, simultaneously with or after HSV-1 infection significantly reduced viral yields. Collectively, BIO-acetoxime may suppress viral gene expression and protect oral epithelial cells from HSV-1 infection. These results suggest the possible involvement of GSK-3 in HSV-1 infection. |
